The European Patent Office (EPO) has published patent application EP4709414A1, detailing a novel vaccine designed to protect against Erysipelothrix Rhusiopathiae and Porcine Parvo Virus. The application lists Intervet International B.V. as the applicant and specifies its designation across numerous European countries, including Germany, France, and the United Kingdom.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it signifies potential advancements in veterinary medicine and may impact future market exclusivity for relevant pharmaceutical companies. Companies involved in animal health or vaccine development should note this filing as part of their competitive landscape monitoring.